Clinical significance of upregulated Rho GTPase activating protein 12 causing resistance to tyrosine kinase inhibitors in hepatocellular carcinoma

doi:10.4251/wjgo.v16.i10.4244

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1794)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-11) series, Tables (1-1) series.

Item

Count

PDF

HTML

1297

Figures (1-11)

114

Tables (1-1)

124

Sum=1571

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

124

Sum=177

Oct 15, 2024 (publication date) through Feb 11, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4244-4263
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4244

Full Size Figure Download Figure

Figure 7 Expression of Rho GTPase activating protein 12 protein in hepatocellular carcinoma tissues. A: Immunohistochemistry staining of control and hepatocellular carcinoma samples; B: Violin plots and receiver operating characteristic curves; C: Comprehensive expression levels of Rho GTPase activating protein 12 protein. ARHGAP12: Rho GTPase activating protein 12; HCC: Hepatocellular carcinoma; SMD: Standardized mean difference; CI: Confidence interval; AUC: Area under the receiver operating characteristic curve.

Citation: Wang XW, Tang YX, Li FX, Wang JL, Yao GP, Zeng DT, Tang YL, Chi BT, Su QY, Huang LQ, Qin DY, Chen G, Feng ZB, He RQ. Clinical significance of upregulated Rho GTPase activating protein 12 causing resistance to tyrosine kinase inhibitors in hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(10): 4244-4263
URL: https://www.wjgnet.com/1948-5204/full/v16/i10/4244.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i10.4244